An Official Website of the United States Government
Development of Innovative Human Stromal Invasion Assay
- Small Business Information
-
Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2005Title: Development of Innovative Human Stromal Invasion AssayAgency: HHSContract: 1R41CA118684-01Award Amount: $99,975.00
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this STTR proposal is to develop an innovative human tumor invasion assay for use as a screening tool in the identification of new anti-tumor therapeutics. Development of a model of early stage tumor invasion, the precursor condition to metastasis, coupled with a highly sensitive readout, is needed to identify new targets for drugs and/or agents that can be used to abrogate the invasion of primary H&N tumors and other types of carcinoma in humans. The NIKS(tm)-based human tumor model developed in the Allen-Hoffmann laboratory permits monitoring tumor cell growth within a normally developed, stratified squamous epithelium. Multiphoton imaging, an important tool for nondestructive investigation of living tissues, provides a highly sensitive readout for the detection of early changes in stroma underlying and/or surrounding tumors. We propose to expand upon our existing NIKS(tm)-NTM model by incorporating human tumor cells that possess a genetically engineered, invasive phenotype, and monitoring the behavior of these cells using multiphoton imaging. The following specific aims will be accomplished during Phase I: (1) Design and construct MT1-MMP expression vector, and demonstrate elevated MT1-MMP mRNA expression levels in transiently-transfected SCC13y cell monolayer cultures, (2) Demonstrate elevated protein expression levels and bioactivity in transiently-transfected SCC13y cell monolayer cultures, and (3) Develop stable, genetically-modified SCC13y cell clones, and evaluate bioactivity of these stable clones utilizing multiphoton microscopy. The unique combination of the novel stromal invasion model with a sophisticated imaging based readout will provide the pharmaceutical industry with a biologically relevant, human cell based, high throughput screening tool to evaluate novel cytostatic agents, and/or gene therapy strategies.Small Business Information at Submission:Research Institution Information:Stratatech Corporation
505 South Rosa Road Suite 169 Madison, WI 53719EIN/Tax ID: 392025292DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: NoUNIVERSITY OF WISCONSIN
4th Floor AW Peterson
750 University Ave
MADISON, WI 53706RI Type: Nonprofit college or university
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: 75489 |
Program Year/Program: 2005 / STTR |
|
Agency Tracking Number: CA118684 |
Solicitation Year: N/A |
Solicitation Topic Code: N/A |
Solicitation Number: N/A |